Longer Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease
Dr. Zaida Morante explains her research that found delaying chemotherapy for more than 30 days was associated with worse outcomes in women diagnosed with early-stage, triple-negative breast cancer. Triple-negative breast cancer is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative.
Listen to the podcast to hear Dr. Morante explain:
the design of the study
which outcomes delaying chemotherapy affected
possible explanations for why chemotherapy was delayed for some women
Dr. Zaida Morante is a medical oncologist at Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru.
— Last updated on May 3, 2022, 3:03 PM
This content made possible by Lilly Oncology.